1. Israel Stocks

  2. •

    Health technology

  3. •

    Medical specialties
ERECH FINANCE CAHALACHA LTD

ERECH FINANCE CAHALACHA LTD

TTASE:EFNC-M
145.80
ILA
-8.20
(-5.32%)
339.10MMarket Cap
ERECH FINANCE CAHALACHA LTD
TASE:EFNC-M
(Tel Aviv Stock Exchange)

Recent

price

145.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
ILS
62.52
235.63
56.41
33.79
49.88
8.1
4.08
5.51
6.08
4.2
0.11
0.07
0.04
- -
Revenue per Share
-14,609.35
-19,534.68
-4,560.6
7.28
21.23
-8.51
-4.13
0.74
0.47
-9.87
-9.97
-3.22
-2.6
- -
Basic EPS, GAAP
-12,862.49
-16,690.25
-5,952.56
41.68
-73.85
-0.35
0.33
-3.72
-4.07
-1.86
-0.86
-0.09
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
1,799.36
45.94
-70.17
24.3
11.34
7.54
14.88
21.13
11.37
1.71
-0.98
-3.06
-3.06
Book Value per Share
- -
1,799.36
45.94
-70.17
24.3
11.34
7.54
14.88
21.13
11.37
1.71
-0.98
-3.06
-3.06
Tangible Book Value per Share
- -
- -
- -
- -
- -
1
2
2
2
3
3
3
3
3
Basic Weighted Avg Shares
- -
1
- -
3
5
10
7
10
13
11
- -
- -
- -
- -
Sales/Revenue/Turnover
-23,084.3
-8,218.56
-8,131.28
35.57
40.83
13.71
-16.87
3.69
19.75
-233.32
-5,535.82
-3,481.22
-6,888.78
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
2
1
- -
- -
- -
- -
- -
Depreciation Expense
-28
-47
-16
1
2
-10
-7
1
1
-25
-25
-8
-7
- -
Net Income, GAAP
- -
- -
- -
48.68
22.66
- -
- -
46.03
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-23,368.6
-8,290.54
-8,085.13
21.54
42.56
-105.02
-101.09
13.36
7.65
-235.14
-8,969.15
-4,574.03
-6,919.39
- -
Profit Margin (%)
- -
5
- -
-1
5
8
- -
13
59
-10
-7
-12
-19
-19
Working Capital
- -
- -
- -
- -
3
13
4
- -
25
- -
4
- -
- -
- -
LT Debt
- -
5
- -
-1
9
18
12
30
53
28
4
-2
-8
-8
Total Equity
- -
- -
- -
- -
10.54
- -
- -
0.49
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
-386.31
14.44
- -
- -
2.25
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-598.22
- -
- -
-73.46
-43.72
6.3
2.43
-60.73
-152.45
- -
- -
- -
Return on Common Equity (%)

Capital Structure

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
16
16
16
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
5
8
3

Working Capital

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
7
3
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
7
3
1
Inventories
- -
- -
- -
Total Current Liabilities
19
19
20
Payables & Accruals
- -
- -
- -
ST Debt
16
16
16
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-144.39%
1.7%
220.65%
Free Cash Flow
-233.72%
-48.32%
-82.43%
Net Income, GAAP
-329.95%
-530.71%
-18.09%
Sales/Revenue/Turnover
163%
-33.31%
-45.86%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-9.97
2024
- -
- -
-3.22
2025
- -
- -
-2.6

Semi-annual Dividends Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Erech Finance Cahalacha Ltd (EFNC-M) operates as an Israel-based financial services and biomedical group, focusing on non-bank credit provision and research and development of biomedicine. The company engages in non-bank lending to small and medium-sized enterprises, associations, and private borrowers in Israel, while pursuing biomedicine initiatives in juvenile diabetes and cancer, including drug development and related research activities. Founded in 1998 and headquartered in Jerusalem, Erech Finance maintains subsidiaries and operates through two primary segments: Non-Bank Credit and Biomed. The group’s geographic reach centers on Israel, with activities and client bases primarily located within the domestic market. Core offerings include: unsecured and secured loan products, credit facilities for SMEs and organizations, credit advisory services, and biomedical R&D programs spanning pharmacological research and development of therapeutics in juvenile diabetes and oncology. The company’s strategic trajectory emphasizes expanding credit reach alongside advancing its Biomed segment through ongoing drug development programs and potential licensing or collaboration opportunities. Recent corporate developments include partnerships and alliances within its financial and biomedicine activities, targeted expansions in lending capacity, and progression of biomedicine projects toward clinical or preclinical milestones, as part of a broader plan to diversify revenue streams and strengthen balance sheet resilience. Erech Finance is listed on the Tel Aviv Stock Exchange under the ticker EFNC-M and operates under a governance structure reflecting its dual focus on financial services and biomedical research, with ongoing considerations for further strategic shifts, acquisitions, or reorganizations to optimize its market positioning and capital efficiency. The company’s footprint, governance, and disclosures align with standard financial data providers’ profiles, emphasizing product breadth, market focus, and recent strategic moves.